<DOC>
	<DOCNO>NCT03029533</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic characteristic safety DWJ108J ( leuprolide acetate ) Leuplin DPS Inj administer subcutaneously patient prostate cancer</brief_summary>
	<brief_title>Phase 1 Study Evaluate Pharmacokinetics Safety Following SC Administration DWJ108J Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Males ≥19 ≤80 year age Screening . 2 . Subject histologically proven adenocarcinoma prostate require androgen deprivation therapy 3 . An ECOG performance status grade 0 2 , 4 . 19kg/m2≤ Body Mass Index ( BMI ) ≤30kg/m2 Screening . 1 . Confirmed Hormone refractory prostate cancer ( HRPC ) 2 . Has history bilateral orchiectomy , suprarenalectomy hypophysectomy . 3 . Diagnosed pituitary adenoma 4 . Has history depression 5 . Has risk spinal cor compression due metastatic spinal cord injury . 6 . Has severe urethratresia . 7 . Confirmed uncontrolled Congestive heart failure ( CHF ) within 6 month Screening . 8 . Has history MI procedure regard coronary artery disease within 6 month Screening . ( e.g. , balloon angioplasty , coronary artery bypass graft ) 9 . Has severe concomitant disease would interfere conduct study except prostate cancer 10 . Has allergy history leuprolide acetate , similar GnRH drug medication ( e.g. , Aspirin , antibiotic ) and/or allergic disease require treatment . 11 . Has receive investigational drug within 9 0days Screening . 12 . Drug release expect administration study drug , subject receive GnRH agonist treatment prostate cancer . 13 . Has chemotherapy plan within 14weeks administration study drug , except androgen deprivation therapy . 14 . Has willing use method contraception throughout study period . 15 . Systolic Blood Pressure &lt; 90mmHg and/or ≥160mmHg Diastolic Blood Pressure &lt; 60mmHg and/or ≥100mmHg Screening 16 . QTcF &gt; 450msec Screening ECG . 17 . HbA1c level high upper limit normal reference range . 18 . Serum AST , ALT Creatinine &gt; 1.5times upper limit normal Screening . 19 . Positive result test hepatitis B , hepatitis C , HIV syphilis . 20 . Has condition , opinion investigator , would make participation best interest subject .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>